XBiotech (NASDAQ:XBIT) Announces Quarterly Earnings Results

XBiotech (NASDAQ:XBIT) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, Zacks reports.

XBiotech Trading Down 2.8 %

Shares of XBiotech stock opened at $3.42 on Wednesday. The stock has a 50-day moving average price of $3.41 and a 200 day moving average price of $5.51. The company has a market cap of $104.25 million, a P/E ratio of -3.17 and a beta of 1.25. XBiotech has a 1 year low of $2.94 and a 1 year high of $9.96.

Institutional Investors Weigh In On XBiotech

An institutional investor recently raised its position in XBiotech stock. Bank of America Corp DE raised its position in shares of XBiotech Inc. (NASDAQ:XBIT) by 42.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,888 shares of the biopharmaceutical company’s stock after purchasing an additional 5,887 shares during the period. Bank of America Corp DE owned 0.07% of XBiotech worth $79,000 as of its most recent SEC filing. Institutional investors own 55.70% of the company’s stock.

XBiotech Company Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.